CLAIMS:

SUB A1

(1) A recombinant MVA containing and capable of expressing one or more DNA sequences encoding dengue virus antigens.

(2) A recombinant MVA according to claim 1 containing and capable of expressing DNA sequences encoding antigens from all four dengue virus serotypes (type 1, 2, 3 and 4).

SUB A2 CONT'D.

(3) A recombinant MVA according to claims 1 to 2, wherein the dengue virus antigen is selected from preM, E and/or NS1 antigens.

(4) A recombinant MVA according to claims 1 to 3, wherein the DNA sequences are inserted at the site of naturally occurring deletions within the MVA genome.

(5) A recombinant MVA according to claims 1 to 4, wherein the DNA sequences encoding antigen is under transcriptional control of the vaccinia virus early/late promoter P7.5.

(6) A vaccine containing at least one recombinant MVA according to claims 1 to 5 and a pharmaceutically acceptable carrier or diluent.

(7) A vaccine according to claim 6 containing a recombinant MVA encoding a dengue virus type 1 antigen; a recombinant MVA encoding a dengue virus type 2 antigen; a recombinant MVA encoding a dengue virus type 3 antigen, and/or a recombinant MVA encoding a dengue virus type 4 antigen, and a pharmaceutically acceptable carrier or diluent.

(8) A method for the treatment or prevention of dengue virus infection comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a recombinant MVA according to claims 1 to 5, or a vaccine according to claims 6 to 7.

(9) A vaccine comprising as a first component a recombinant MVA carrying and capable of expressing T7 RNA polymerase and as further components one or more recombinant DNA vectors each carrying at least one

dengue virus antigen under transcriptional control of a T7 RNA polymerase promoter.

(10) A method for the treatment or prevention of a dengue virus infection comprising inoculating a living animal body, including a human, in need thereof with the first and further components of a vaccine according to claim 9 either simultaneously or with a timelag but using the same inoculation site.

Sub A3 cancels.

ADD A3

add B1

C2 Add claims 32-38

SUBSTITUTE SHEET (RULE 26)